Additionally, DX2-145, a GRP78 Proteolysis Targeting Chimera developed by incorporating YUM70, a linker and an E3-recruiting ligand, elicited partial degradation of GRP78 in cancer cells, suggesting the feasibility of this exciting new approach to eliminate GRP78 in the tumor (102). This evidence concerns the gene HSPA5 and neoplasm.